Your Complete Guide to Global Clinical Research and GCP Compliance
Future Trends in AI, Real-World Data, and Evolving Rules for Plain-Language Summaries & Layperson Results As the landscape of clinical trials continues to evolve, several key trends are making significant impacts. Innovations in artificial intelligence (AI), the incorporation of real-world data (RWD), and the development of regulatory guidelines are shaping how clinical trial results are…
Training Clinical, Regulatory and Medical Teams on Plain-Language Summaries & Layperson Results Training Clinical, Regulatory and Medical Teams on Plain-Language Summaries & Layperson Results In the domain of clinical trials, the dissemination of results is a critical component of transparency and public trust. This article serves as a comprehensive guide for training clinical operations, regulatory…
Using Plain-Language Summaries & Layperson Results to Support Publications, HTA and Market Access Using Plain-Language Summaries & Layperson Results to Support Publications, HTA and Market Access In the ever-evolving landscape of clinical trials, the importance of effective communication cannot be overstated. Particularly in the context of providing transparent and comprehensible information to patients, stakeholders, and…
Integrating Plain-Language Summaries & Layperson Results With Data Privacy, GDPR and HIPAA Requirements Integrating Plain-Language Summaries & Layperson Results With Data Privacy, GDPR and HIPAA Requirements In the realm of clinical research, the significance of transparency and effective communication cannot be overstated. The emergence of requirements for plain-language summaries and layperson results reinforces this necessity….
Vendor and Partner Oversight Considerations for Plain-Language Summaries & Layperson Results Vendor and Partner Oversight Considerations for Plain-Language Summaries & Layperson Results In the evolving landscape of clinical trials, transparency remains a keystone, especially concerning layperson results and plain-language summaries. As the regulatory environment intensifies, especially within the jurisdictions of the FDA, EMA, and MHRA,…
KRIs, KPIs and Dashboards to Monitor Plain-Language Summaries & Layperson Results Across Portfolios KRIs, KPIs and Dashboards to Monitor Plain-Language Summaries & Layperson Results Across Portfolios In today’s clinical research landscape, transparency and clear communication with stakeholders are crucial. Key Risk Indicators (KRIs), Key Performance Indicators (KPIs), and dashboards are essential tools used by clinical…
Case Studies: Plain-Language Summaries & Layperson Results That Strengthened Public and Regulator Trust Case Studies: Plain-Language Summaries & Layperson Results That Strengthened Public and Regulator Trust Introduction to Plain-Language Summaries in Clinical Trials Plain-language summaries (PLS) have emerged as a critical component in enhancing transparency and public trust in clinical trials, particularly in the context…
Digital Tools and Automation to Streamline Plain-Language Summaries & Layperson Results In the ever-evolving landscape of clinical trials, keeping pace with regulatory requirements and enhancing transparency is crucial. One area that is often overlooked yet significantly important is the provision of plain-language summaries (PLS) and layperson results. These documents serve to convey complex clinical trial…
Inspection and Audit Readiness: Documenting Plain-Language Summaries & Layperson Results for Regulators Inspection and Audit Readiness: Documenting Plain-Language Summaries & Layperson Results for Regulators As clinical trials become increasingly complex and subject to scrutiny by regulatory bodies, ensuring transparency through proper documentation has never been more crucial. This guide aims to equip clinical operations, regulatory…
Aligning Plain-Language Summaries & Layperson Results With ICH, GCP and Transparency Regulations In the evolving landscape of clinical research, ensuring clear communication of trial results is paramount. Regulatory bodies such as the FDA, EMA, and MHRA emphasize the importance of transparency, specifically through the use of plain-language summaries and layperson results. This article aims to…